SOUTH SAN FRANCISCO, Calif., September 28, 2022 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. ALGSA clinical-stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in viral and liver diseases has issued a response to Janssen Biopharma’s complaint and counterclaims against Janssen Biopharma in California State Superior Court for the District submitted to San Mateo.

Specifically, the response to Janssen’s complaint identifies the Aligos co-founders’ decades-old publicly available information (published patents and scientific literature), previous work experience, publications and patents at other oligonucleotide companies in relation to the initial discovery of oligonucleotides (ASO and siRNA). hepatitis B virus (HBV), as well as the licenses Aligos has received from universities and biotechnology companies – all of which have been used as the basis for Aligos’ HBV portfolio. The reply further elaborates and documents that all work was carried out by Aligos employees after they left Janssen Biopharma.

The counterclaims against Janssen accuse Janssen of unfair competition and promissory note fraud. Aligos co-founders Lawrence M. Blatt, Ph.D., MBA, and Leonid Beigelman, Ph.D. joined Aligos in filing the counterclaims. That answer and counterclaims can be found under the respective hyperlinks.

“I encourage anyone interested in this matter to read our response and counterclaim,” said Lawrence M. Blatt, Ph.D., MBA, CEO, Chairman and Co-Founder of Aligos. “The facts are on Aligos’ side and we will continue to defend ourselves against Janssen’s unfounded allegations.”

About Aligos

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 with the goal of becoming a global leader in the treatment of viral infections and liver diseases. Aligos is focused on discovering and developing targeted antiviral therapies for chronic hepatitis B (CHB) and coronaviruses and leveraging its…